Core Points - The controlling shareholder of HeFu China (603122), HeFu (Hong Kong) Holdings Limited, plans to reduce its stake in the company by a total of up to 7.9611 million shares, which represents no more than 2% of the company's total share capital [1] Summary by Category Company Actions - HeFu (Hong Kong) Holdings Limited intends to execute the share reduction through block trades and centralized bidding [1] Shareholder Information - The planned reduction involves a significant number of shares, specifically up to 7.9611 million, indicating a strategic move by the controlling shareholder [1] Market Impact - The reduction of up to 2% of the total share capital may influence market perception and trading activity of HeFu China shares [1]

合富（中国）医疗科技股份有限公司 控股股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603122 证券简称：合富中国 公告编号：临 2025-065 控股股东持股的基本情况：本次减持计划实施前，合富（中国）医疗科 技股份有限公司（以下简称"公司"）控股股东合富（香港）控股有限公司持有 公司股票 218,937,885 股，占公司总股本的 55.00%，上述股份全部来源于公司 IPO 前取得，均为无限售流通股。 预披露期间，若公司股票发生停牌情形的，实际开始减持的时间根据停牌时 间相应顺延。 (一)相关股东是否有其他安排 □是 √否 (二)大股东及董监高此前对持股比例、持股数量、持股期限、减持方式、减 持数量、减持价格等是否作出承诺 √是 □否 控股股东在公司 IPO 时作出相关承诺如下： 减持计划的主要内容：合富（香港）控股有限公司计划通过大宗交易方 式和集中竞价交易方式减持公司股份数量合计不超过 7,961,052 股（合计不超过 公司总股本的 2%），其中通过大宗 ...

Group 1 - The core point of the article is that the controlling shareholder of HeFu China plans to reduce its stake in the company through block trades and centralized bidding, with a total reduction not exceeding 7.9611 million shares, which accounts for up to 2% of the company's total share capital [1] Group 2 - The reduction will be executed via two methods: block trading and centralized bidding [1] - The total number of shares to be reduced is 7.9611 million [1] - This reduction represents a significant portion of the company's total share capital, specifically 2% [1]

证券代码：603122 证券简称：合富中国 公告编号：临 2025-063 合富（中国）医疗科技股份有限公司 关于全资子公司向关联方销售设备 的日常关联交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 关联交易内容：合富（中国）医疗科技股份有限公司（以下简称"合富 中国"或"公司"）之全资子公司香港商合玺医疗器材有限公司台湾分公司（以 下简称"合玺香港台湾分公司"）因业务需要拟向关联方英属盖曼群岛商合富医 疗器材股份有限公司台湾分公司（以下简称"合富医疗台湾分公司"）销售 1 台磁振造影即時导航放射治疗系统（ViewRay MRIdian Linac System，以下简称 "ViewRay 设备"）。 本次关联交易需提交公司股东会审议。 本次日常关联交易对公司的影响：本次销售遵循公平、合理的原则协商 定价，不会对公司的独立性产生影响，公司不会因此对关联方产生较大的依赖， 不会对公司正常生产经营、财务状况产生重大不利影响，亦不会损害公司股东特 别是中小股东的利益。 一、日常关联交易基本情况 应中国台湾某 ...

合富（中国）医疗科技股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 召开的日期时间：2025 年 12 月 19 日 14 点 30 分 召开地点：上海市徐汇区虹漕路 456 号光启大楼 20 楼会议室 (五)网络投票的系统、起止日期和投票时间。 证券代码：603122 证券简称：合富中国 公告编号：临 2025-064 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运 作》等有关规定执行。 (七)涉及公开征集股东投票权 无。 二、会议审议事项 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 19 日 至2025 年 12 月 19 日 股东会召开日期：2025年12月19日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (一)股东会类型和届次 2025年第二次临时股东会 (二)股东会 ...

合富（中国）医疗科技股份有限公司 证券代码：603122 证券简称：合富中国 公告编号：临 2025-062 与会董事认真审议了所有议案，经书面投票表决，形成了如下决议： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 合富（中国）医疗科技股份有限公司（以下简称"公司"）第三届董事会第 四次会议于 2025 年 12 月 2 日下午以书面传签方式召开，经全体董事一致同意豁 免本次会议的通知时限要求，会议通知于 2025 年 12 月 2 日以电子邮件方式发出。 本次会议应出席董事 6 人，实际出席董事 6 人。董事会秘书及部分高级管理人员 列席了会议。会议的召集、召开程序符合法律法规、《公司法》及《公司章程》 的规定，会议决议合法、有效。 二、董事会会议审议情况 1、审议并通过了《关于全资子公司向关联方销售设备的日常关联交易议案》。 第三届董事会第四次会议决议公告 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《关 于全资子公司向关联方销售设备的日常关联交易公告》（公告编 ...

Core Viewpoint - The controlling shareholder of HeFu China plans to reduce its stake in the company by up to 7.96 million shares, which is no more than 2% of the total share capital, to meet operational funding needs [1] Group 1: Shareholder Actions - HeFu (Hong Kong) Holdings Limited intends to sell shares through block trading and centralized bidding [1] - The reason for the share reduction is to raise funds for operational needs, including a project related to magnetic resonance imaging navigation radiation therapy systems [1] Group 2: Market Performance - HeFu China has been a strong performer in the secondary market, with a cumulative increase of 282.63% from October 28 to December 2 [1] - On December 2, HeFu China reached its daily limit, closing up 9.98% at a price of 25.56 yuan per share [1]

Core Viewpoint - The controlling shareholder of HeFu China plans to reduce its stake in the company by up to 7,961,052 shares, representing a maximum of 2% of the total share capital [1] Summary by Category Share Reduction Plan - The reduction will occur through two methods: block trading and centralized bidding, with each method allowing for a maximum reduction of 3,980,526 shares, or 1% of the total share capital [1] - The reduction plan will be executed within three months starting from 15 trading days after the announcement [1] - The selling price will be determined based on market conditions [1]

Core Viewpoint - The controlling shareholder of HeFu China, HeFu Hong Kong, plans to reduce its stake by up to 796.11 million shares (2%) within three months through block trades and centralized bidding, with the proceeds aimed at enhancing operational funds and supporting specific projects [1] Group 1 - HeFu Hong Kong currently holds 219 million shares, representing 55.00% of HeFu China's total shares [1] - The planned reduction includes a maximum of 398.05 million shares (1%) through block trades and another 398.05 million shares (1%) through centralized bidding [1] - The shares to be sold are all pre-IPO unrestricted circulating shares, indicating that they were acquired before the company's initial public offering [1] Group 2 - The funds raised from the share reduction will be used to support operational needs, including the development of a magnetic resonance imaging (MRI) navigation radiation therapy system project [1]

Core Viewpoint - The stock of HeFu China (603122) experienced a trading halt today, with a turnover rate of 25.13% and a transaction volume of 2.478 billion yuan, indicating significant market activity [2][3]. Trading Activity - The stock was listed on the Shanghai Stock Exchange's daily trading report due to its turnover rate reaching 25.13%, with a net selling amount of 28.5454 million yuan from brokerage seats [2]. - The top five brokerage seats accounted for a total transaction volume of 302 million yuan, with buying transactions amounting to 137 million yuan and selling transactions totaling 165 million yuan, resulting in a net sell of 28.5454 million yuan [2]. - The largest buying brokerage was Guosen Securities Co., Ltd. Zhejiang Internet Branch, with a purchase amount of 45.0835 million yuan, while the largest selling brokerage was Guotai Junan Securities Co., Ltd. Shanghai Changning District Jiangsu Road Branch, with a selling amount of 47.2253 million yuan [2][3]. Stock Performance - Over the past six months, the stock has appeared on the trading report 14 times, with an average price increase of 5.97% the day after being listed and an average increase of 34.49% over the following five days [3]. - Today, the stock saw a net inflow of 32.7809 million yuan in main funds, with a significant single order net inflow of 10.6744 million yuan and a large order net inflow of 22.1064 million yuan. However, there was a net outflow of 148 million yuan in the past five days [3]. Financial Performance - The company reported its third-quarter results on October 30, showing a total revenue of 549 million yuan for the first three quarters, a year-on-year decrease of 22.80%, and a net loss of 12.3862 million yuan [3].